Skip to main content
. 2014 Apr 30;5(22):11193–11208. doi: 10.18632/oncotarget.1933

Figure 2. PPP synergistically enhances the anti-myeloma activity of ABT-737.

Figure 2

A-D: PPP + ABT-737 synergistically decreased HMCL viability. RPMI-8226 (A, C) and OPM-2 (B, D) cells were cultured with 0 nM (black bars), 125 nM (dark grey), 250 nM (light grey) or 500 nM (white) PPP either alone or in combination with indicated concentrations of ABT-737 for 24h (A, B) and 48h (C, D). A-D: Effect on cell viability was evaluated by using a CellTiter-Glo Assay. Results are expressed as the relative viability compared to control cells. Bars and error bars indicate mean ± SD of at least 3 independent experiments. P-values and combination indexes after 48h are shown in Table 1. E-F: Effect of co-treatment on primary human MM cells. CD138+ cells were purified from BM aspirates from 9 MM patients. E: Primary MM cells of patient 1, 2, 3, 5 and 6 were treated with 1 μM PPP, 500 nM ABT-737 or a combination of both. F: Primary MM cells of patient 4, 7, 8 and 9 were treated with 1 μM PPP, 125 nM ABT-737 or a combination of both. The effect on cell viability was determined by the CellTiter-Glo assay after 24h. Results are expressed as the relative viability compared to untreated cells. # indicates patient number.